Characterization of ATP-induced cell death in the GL261 mouse glioma

Alessandra S K Tamajusuku1, Emilly S Villodre, Romela Paulus

  • 1Departamento de Biofísica, Porto Alegre, RS, Brazil.

Insights

Extracellular ATP induces glioma cell death primarily through necrosis, mediated by the P2X7 receptor. This finding highlights a potential therapeutic target for aggressive brain tumors.

Area of Science:

  • Neuro-oncology
  • Cellular Biology
  • Biochemistry

Background:

  • Gliomas are aggressive brain tumors with poor prognoses.
  • Resistance to cell death pathways contributes to glioma progression.
  • Extracellular ATP (adenosine triphosphate) has been implicated in glioma pathobiology.

Purpose of the Study:

  • To investigate the mechanisms of cell death induced by extracellular ATP in a murine glioma cell line (GL261).
  • To determine the role of the P2X7 receptor in ATP-mediated glioma cell death.
  • To elucidate the type of cell death (apoptotic vs. necrotic) induced by extracellular ATP.

Main Methods:

  • Utilized GL261 murine glioma cells.
  • Administered ATP and BzATP (P2X7 agonist) to induce cell death.
  • Employed oATP (P2X7 antagonist) to block ATP-induced cell death.
  • Used RNA interference to reduce P2X7 receptor expression.
  • Assessed cell death markers, including phosphatidylserine externalization and caspase activity.

Main Results:

  • ATP and BzATP induced cell death in GL261 cells.
  • P2X7 receptor activation was necessary for ATP-induced cell death, as shown by antagonist and RNA interference studies.
  • A subpopulation of cells with higher P2X7 expression was more sensitive to ATP.
  • ATP-induced cell death was predominantly necrotic, characterized by cell shrinkage and membrane permeabilization, not apoptosis.

Conclusions:

  • The P2X7 receptor is crucial for mediating extracellular ATP-induced cell death in glioma cells.
  • The findings suggest that necrosis, rather than apoptosis, is the primary mechanism of cell death.
  • Targeting P2X7-mediated cell death could offer a novel therapeutic strategy for gliomas.